InvestorsHub Logo
Followers 46
Posts 3929
Boards Moderated 0
Alias Born 03/04/2012

Re: george h post# 269005

Monday, 07/29/2019 12:48:18 AM

Monday, July 29, 2019 12:48:18 AM

Post# of 403766
Good goin' george, hope IPIX gets a lot more attention as the company successfully develops many of their Brilacidin indications.

This first one, for their smallest market indication (UP/UPS), puts this company on the GI map. Now we need to replicate previous good results, and maybe even better with foam "retention" in the lower colon.

I just sent an email to several staff members of "Endpoints News" a pharma news journal:

I'd like to call to your attention the recent press release of IPIX, Innovation Pharmaceuticals, regarding their deal with the Italian pharma co., Alphasigma:
INNOVATION PHARMACEUTICALS ANNOUNCES LICENSE AGREEMENT WITH ALFASIGMA S.P.A. FOR THE DEVELOPMENT AND COMMERCIALIZATION OF BRILACIDIN IN ULCERATIVE PROCTITIS/ULCERATIVE PROCTOSIGMOIDITIS
Brilacidin is been successful in several studies. I hope you will investigate and report about this promising development.
Disclosure: I am a shareholder of IPIX.
Thanks,
gh